EVIVE Biotechnology
11
0
0
8
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
18.2%
2 terminated/withdrawn out of 11 trials
80.0%
-6.5% vs industry average
27%
3 trials in Phase 3/4
88%
7 of 8 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (11)
Study to Compare the Efficacy and Safety of F-627 and GRAN®
Role: lead
Study of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy
Role: lead
Study of F-652 (IL-22:IgG2 Fusion Protein) in Patients With Moderate to Severe COVID-19
Role: lead
Study of F-652 in Subjects With Corona Virus Disease 2019 (COVID-19) Pneumonia
Role: lead
Neulasta-controlled Trial of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy
Role: lead
Study of IL-22 IgG2-Fc (F-652) for Subjects With Grade II-IV Lower GI aGVHD
Role: lead
Placebo-controlled Trial of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy
Role: lead
A Pharmacokinetics/Dynamics Ib Study of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy
Role: lead
Study of A-319 in Patients With Relapsed or Refractory B-cell Lymphoma
Role: lead
Dose-Finding Trial of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy
Role: lead
A Phase II, Dose-finding Study of F-627 in Patients With Breast Cancer Receiving Myelotoxic Chemotherapy.
Role: lead
All 11 trials loaded